OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
415056

Unicon Optical Co Ltd

Medical Equipment, Supplies & DistributionVerified

Unicon Optical Co Ltd has a liquidity ratio of 1.4, indicating that it has $1.40 in current assets for every $1 of current liabilities. However, the company's free cash flow is negative at -$272.71 million, and its operating cash flow is also negative at -$184.38 million, suggesting that the company is not generating sufficient cash from operations to fund its activities. The company's debt-to-equity ratio is 0.8, which is relatively low, but its return on equity is -56.22%, and its return on assets is -25.89%, indicating poor profitability. The company's profitability metrics are significantly below industry norms, with a negative return on equity and return on assets. This suggests that the company is not effectively utilizing its assets or equity to generate profits. The negative gross profit of -$42.91 million and operating income of -$241.08 million further highlight the company's financial distress. Unicon Optical Co Ltd's revenue is primarily derived from the sale of contact lenses, with no specific segment breakdown provided. The company operates in both domestic and international markets, but the exact geographic distribution of its revenue is not disclosed. This lack of geographic diversification could pose a risk if the company's domestic market experiences economic downturns. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The negative operating and net income figures suggest that the company is not currently in a growth phase and may be facing operational challenges. The company's capital expenditure of -$60.53 million indicates that it is not investing in new projects or expanding its operations. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. However, the key flag of negative net cash after subtracting total debt suggests that the company may face liquidity constraints in the near term. The company's financial performance and profitability are major concerns, and any further deterioration could increase the risk of dilution. Recent events and filings do not provide specific details on the company's recent performance or strategic initiatives. The company's financial statements indicate ongoing losses and negative cash flows, which may impact its ability to meet short-term obligations and invest in future growth.

30-day price · 4150+0.84 (+16.4%)
Low$3.59High$7.85Close$5.95As of15 May, 00:00 UTC
Profile
CompanyUnicon Optical Co Ltd
Ticker4150.TWO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Unicon Optical Co Ltd produces and sells contact lenses, including daily disposable, monthly disposable, make-up, hydrophobic, and drug release lenses, primarily for vision correction and cosmetic purposes.

Classification. Unicon Optical Co Ltd is classified under the Healthcare sector, specifically in the Medical Equipment, Supplies & Distribution industry, with a confidence level of 0.92.

Unicon Optical Co Ltd has a liquidity ratio of 1.4, indicating that it has $1.40 in current assets for every $1 of current liabilities. However, the company's free cash flow is negative at -$272.71 million, and its operating cash flow is also negative at -$184.38 million, suggesting that the company is not generating sufficient cash from operations to fund its activities. The company's debt-to-equity ratio is 0.8, which is relatively low, but its return on equity is -56.22%, and its return on assets is -25.89%, indicating poor profitability. The company's profitability metrics are significantly below industry norms, with a negative return on equity and return on assets. This suggests that the company is not effectively utilizing its assets or equity to generate profits. The negative gross profit of -$42.91 million and operating income of -$241.08 million further highlight the company's financial distress. Unicon Optical Co Ltd's revenue is primarily derived from the sale of contact lenses, with no specific segment breakdown provided. The company operates in both domestic and international markets, but the exact geographic distribution of its revenue is not disclosed. This lack of geographic diversification could pose a risk if the company's domestic market experiences economic downturns. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The negative operating and net income figures suggest that the company is not currently in a growth phase and may be facing operational challenges. The company's capital expenditure of -$60.53 million indicates that it is not investing in new projects or expanding its operations. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. However, the key flag of negative net cash after subtracting total debt suggests that the company may face liquidity constraints in the near term. The company's financial performance and profitability are major concerns, and any further deterioration could increase the risk of dilution. Recent events and filings do not provide specific details on the company's recent performance or strategic initiatives. The company's financial statements indicate ongoing losses and negative cash flows, which may impact its ability to meet short-term obligations and invest in future growth.
Key takeaways
  • Unicon Optical Co Ltd is experiencing significant financial distress, with negative profitability and cash flow metrics.
  • The company's liquidity position is moderate, but its negative free cash flow and operating cash flow are concerning.
  • The company's return on equity and return on assets are well below industry norms, indicating poor asset and equity utilization.
  • The company's geographic and segment revenue distribution is not disclosed, which could pose a risk if the domestic market is underperforming.
  • The company's capital expenditure is negative, suggesting a lack of investment in growth opportunities.
  • The company's risk assessment highlights a medium liquidity risk and a low dilution risk, but the negative net cash position is a key concern.
  • # RATIONALES
  • **margin_outlook_rationale**: The company's negative gross profit and operating income suggest that its margins are deteriorating, driven by high costs and low sales.
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$641.1M
Gross profit-$42.9M
Operating income-$241.1M
Net income-$274.0M
R&D
SG&A
D&A
SBC
Operating cash flow-$184.4M
CapEx-$60.5M
Free cash flow-$272.7M
Total assets$1.06B
Total liabilities$570.8M
Total equity$487.3M
Cash & equivalents$149.1M
Long-term debt$390.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$487.3M
Net cash-$240.9M
Current ratio1.4
Debt/Equity0.8
ROA-25.9%
ROE-56.2%
Cash conversion67.0%
CapEx/Revenue-9.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric4150Activity
Op margin-37.6%13.3% medp25 5.9% · p75 13.5%bottom quartile
Net margin-42.7%8.6% medp25 2.7% · p75 12.7%bottom quartile
Gross margin-6.7%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-9.4%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity80.0%69.3% medp25 63.4% · p75 74.5%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 15:35 UTC#46bf1fe8
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 14:11 UTCJob: 9895306f